|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
BOND-003 Cohort C: Durability of Responses Examined with Cretostimogene in BCG-Unresponsive Bladder Cancer
|
|
Shreyas Joshi, MD, MPH
|
| Shreyas Joshi review 24-month durability data from BOND-003 Cohort C, a study of cretostimogene grenadenorepvec in BCG-unresponsive CIS patients.
|
|
|
|
|
|
|
|
|
|
|
|
|
Subgroup Findings from CREST Trial in High-Risk Bladder Cancer
|
|
Gary Steinberg, MD
|
| Gary Steinberg discusses CREST trial subgroup analysis of very high-risk BCG-naive NMIBC. The trial randomized 1,055 patients to sasanlimab plus BCG versus BCG alone with overall hazard ratio 0.68 at 36 months.
|
|
|
|
|
|
|
|
|
|
|
|
|
Navigating Treatment Options and Trial Designs for Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Vignesh Packiam, MD
|
| Vignesh Packiam outlines emerging intermediate-risk NMIBC trials from SUO 2025. ZUSDURI™ (mitomycin) received FDA approval with 80% complete response in chemo-ablation studies.
|
|
|
|
|
|
|
|
|
|
|
|
| Durable 24-Month Outcomes from BOND-003 Cohort C: Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec for High-Risk BCG-Unresponsive Nonmuscle-Invasive Bladder Cancer with CIS
|
| Shreyas Joshi, MD, MPH
|
| In the phase 3 BOND-003 trial, cretostimogene grenadenorepvec achieved a 75.5% complete response rate in 112 patients with high-risk BCG-unresponsive NMIBC with CIS, with 42% 24-month CR, 60% 24-month duration of response, 96% free from ≥T2 progression, and 84% cystectomy-free at median 25.8-month follow-up.
|
|
|
|
|
|
| BCG-Naïve NMIBC in 2025: Are We Moving Beyond BCG Alone?
|
| Evanguelos Xylinas, MD, PhD, FEBU
|
| Evanguelos Xylinas reviewed BCG-naïve high-risk NMIBC intensification: ALBAN negative, but CREST/POTOMAC positive, driven by high-grade recurrence reduction vs historical BCG. Benefits clinically meaningful, toxicities manageable, no OS detriment; broad applicability including very-high-risk/CIS/T1.
|
|
|
|
|
|
|
|
|
|
|
| UGN-102 for Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer: 5-Year Long-Term Extension Study Results from the Single-Arm, Phase 2B OPTIMA II Study
|
| William Huang, MD
|
| Long-term follow-up from the phase 2b OPTIMA II study highlights the durability of chemoablative treatment with UGN-102 in patients with low-grade, intermediate-risk NMIBC, with outcomes assessed over a 5-year period.
|
|
|
|
|
|
| Trial Design Drives Outcomes: Harmonizing Efficacy Across BCG-Unresponsive Bladder Carcinoma in Situ Trials
|
| Daniele Robesti, MD
|
| At the European Association of Urology Annual Congress 2026, Daniele Robesti showed that differences in trial design—such as biopsy requirements, timing of response assessment, and retreatment policies—significantly impact reported efficacy outcomes in BCG-unresponsive carcinoma in situ studies. These variations can introduce bias and make cross-trial comparisons unreliable, sometimes inflating complete response rates.
|
|
|
|
|
|
|
|
|
|
|
